Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Master protocol of two randomized, double blind, placebo-controlled, multicenter, parallel group studies to evaluate the efficacy and safety of dupilumab in adult patients with chronic pruritus of unknown origin (CPUO)

Next Previous
Search
Trial Profile

Master protocol of two randomized, double blind, placebo-controlled, multicenter, parallel group studies to evaluate the efficacy and safety of dupilumab in adult patients with chronic pruritus of unknown origin (CPUO)

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dupilumab (Primary) ; Fexofenadine (Primary)
  • Indications Pruritus
  • Focus Registrational; Therapeutic Use
  • Acronyms LIBERTY-CPUO-CHIC
  • Sponsors Sanofi; Sanofi-Aventis Recherche & Developpement

    • Most Recent Events

    • 11 Sep 2024 According to Regeneron Pharmaceuticals media release, study B is planned to initiate as a subsequent pivotal study, Detailed efficacy and safety results for both BP and CPUO studies are planned for presentation at a forthcoming medical meeting.
    • 11 Sep 2024 According to a Sanofi media release, Detailed efficacy and safety results for this study is planned for presentation at a forthcoming medical meeting.The safety and efficacy of Dupixent in CPUO is currently under clinical investigation and have not been evaluated by any regulatory authority.
    • 01 Sep 2024 Primary endpoint (Study A) has not been met, according to a Sanofi media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top